Lilly taps obesity windfall for more M&A. Plus, Elon Musk remarks pull GE Vernova lower

Stocks start the week broadly lower as U.S.-Iran tensions lift oil: WTI rises back above $85/bbl and Brent above $90/bbl. The hawkish Jackson Hole speech contributes to bond pressure, with the 10-year Treasury yield climbing to ~4.75%. On deals, Eli Lilly agreed to acquire Merida Biosciences for up to $2.875B cash, while GE Vernova trades ~2% lower on concerns about SpaceX in-house casting potentially delaying turbine production (Jefferies flags bottlenecks lasting years). Key upcoming catalysts include S&P Global/ISM manufacturing PMIs, construction spending, and JOLTS job openings/quits.

Analysis

The weekend shock is less about immediate substitution and more about reinforcing a multi-quarter bottleneck premium in industrial power equipment. Even if a credible new entrant eventually internalizes blade casting, the qualification cycle in mission-critical components is long enough that incumbents should keep pricing power; the first-order loser is not today’s revenue, but the multiple if investors assume competitive erosion arrives faster than it can. In that sense, the selloff in GEV/HWM looks more like a sentiment event than a fundamental reset.

The bigger second-order risk for GEV is not the announced threat itself, but capital formation: higher oil plus a 10-year near 4.75% raises the hurdle rate for data-center, grid, and generation projects that underpin backlog growth. If financing conditions stay tight for 1-3 months, order timing can slip even without any change in end-demand, which would matter more than a single social-media headline. That makes GEV a good company but a less clean macro hedge than the market may think.

On obesity-drug coverage, the market is still treating employer coverage as a binary win/loss, but the more important mechanism is whether employers optimize for near-term pharmacy spend or longer-dated medical cost deflation. The consensus may be underestimating how sticky the latter is, which supports LLY’s category power over 6-18 months; however, there is no obvious direct equity trade in PEP from one benefits decision. The more interesting watch item is whether peers follow, which would pressure payer negotiations and amplify pricing scrutiny on GLP-1s into year-end.

Key Decisions for Investors

• Buy GEV on 1-3 day weakness only if the stock holds most of the opening gap; target 2-3x upside to the next earnings catalyst, with a stop if 10Y yields keep rising and project-finance commentary turns negative.
• Tactically buy HWM on an exaggerated open selloff; the insourcing threat is a 3-4 year story, so downside from the headline should fade unless an OEM names a qualified alternate supplier this year.
• Avoid chasing PEP on the GLP-1 coverage debate; treat it as a monitoring item, not a thesis, unless multiple large employers reverse course and pharmacy benefit commentary starts showing broad exclusion trends.
• Set a watch on GEV backlog and order conversion over the next 1-2 quarters; if data-center permit delays or customer deferrals appear, reduce exposure even if the competitive bottleneck narrative remains intact.